Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 5 years, with Dec 2024 value amounting to $77.7 million.

  • Iovance Biotherapeutics' Total Non-Current Liabilities was N/A to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year change of. This contributed to the annual value of $77.7 million for FY2024, which is 9.07% down from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Total Non-Current Liabilities is $77.7 million, which was down 9.07% from $85.4 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Total Non-Current Liabilities high stood at $85.4 million for FY2023, and its period low was $77.7 million during FY2024.
  • In the last 2 years, Iovance Biotherapeutics' Total Non-Current Liabilities had a median value of $81.6 million in 2023 and averaged $81.6 million.
  • Data for Iovance Biotherapeutics' Total Non-Current Liabilities shows a maximum YoY fell of 9.07% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Total Non-Current Liabilities stood at $85.4 million in 2023, then decreased by 9.07% to $77.7 million in 2024.